- The
program focuses on the pursuit of reduced risk oral nicotine products that
make use of Lexaria’s patented DehydraTECH drug delivery platform
- DehydraTECH
has been studied extensively and both human/animal trials confirm its
ability to enhance active ingredient absorption in digestible products
- The
current research could contribute to the development of oral nicotine
products that would usher in a new era of reduced-risk nicotine use
Global innovator in drug delivery platforms Lexaria
Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) provided an extensive update
on advances in its research and development program with Altria Ventures Inc.,
an indirect wholly owned subsidiary of Altria Group, Inc (NYSE: MO). The
collaboration focuses on the pursuit of reduced risk oral nicotine consumer
products using the Lexaria-patented DehydraTECH technology.
Most of the work within the first phase of the collaborative
project has either been completed or is significantly underway. Only one aspect
of the project remains to commence imminently, according to a company press
release issued on October 8, 2019 (http://ibn.fm/Czxkv).
The successful completion of the first phase of the program
will be the first step in developing viable products with Lexaria’s DehydraTECH
drug delivery platform. Under the terms and conditions of the agreement,
Lexaria’s majority owned subsidiary Lexaria Nicotine LLC will see royalties
being paid from any sold oral nicotine products, in the event of Altria
deciding to use the technology in the U.S. or overseas.
Due to the advances in the program, the two partners have
been thoroughly studying the process of oral nicotine administration. Lexaria
Bioscience and Lexaria Nicotine CEO Chris Bunka said, “Lexaria strongly
believes that, given the choice, many of the world’s one billion smokers would
elect to experience their nicotine in a manner that does not rely on either
smoking or vaping, and Lexaria can help enable these alternatives.”
Lexaria’s philosophy is that the oral administration of
nicotine can provide a reduced-risk access to the substance, providing better
health outcomes than standard combustible cigarettes.
The DehydraTECH technology is a vital component for product
development. Human and animal clinical studies have demonstrated DehydraTECH’s
ability to enhance bio-absorption and bioavailability of active compounds in
oral administration products.
The technology has a wide scope of additional applications.
DehydraTECH can improve taste, remove odor and bring down the time to onset in
the case of delivering active ingredients within generally recognized as safe
(GRAS) food ingredients. Because of its superior performance characteristics,
the technology is also being used by the CBD industry. Research suggested that
CBD absorption into human intestinal cells increased by 499 percent through the
utilization of the DehydraTECH technology.
Similar results were observed in previous animal studies,
suggesting a massive increase in absorption (811 percent) when comparison was
made with a control group.
Lexaria has also completed several phases of collaborative
study with the National Research Council in Canada (http://ibn.fm/UC2eZ). Several
work programs were designed to evaluate and characterized the DehydraTECH
technology utilizing nuclear magnetic resonance and other advanced methods of
study such as DLS and Zeta Potential analysis.
Lexaria Bioscience is a global innovator in drug delivery
platforms. It operates a licensed in-house research laboratory and the company
also holds an impressive portfolio of 16 patents granted and over 60 patents
pending.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
